Pediatrix Medical Group, Inc.
No SEC Form 4 filings for $MD in the last 30 days.
See all $MD insider activity →Pediatrix Medical Group (MD) reported Q2 2026 revenue of $487.8 million, up 4% y/y, with adjusted EPS of $0.63 and adjusted EBITDA of $76.4 million. Net income was $39.8 million. Patient volume fell 2.1% y/y, while same-unit pricing rose 4%. CFO Rossi reaffirmed full-year 2026 adjusted EBITDA guidance of $280 million to $300 million.
Pediatrix Medical Group, Inc. (MD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 md-ex99_1.htm EX-99.1 EX-99.1 FOR MORE INFORMATION: Kasandra H. Rossi Executive Vice President, Chief Financial Officer & Treasurer 954-692-7163 kasandra.rossi@pediatrix.com FOR IMMEDIATE RELEASE Pediatrix Medical Group Reports Second Quarter Results FORT LAUDERDALE, Fl
Pediatrix Medical Group (NYSE:MD) reported Q2 CY2026 revenue of $487.8 million, up 4% year on year, beating market expectations by 2.1% (per the article). Non-GAAP adjusted EPS was $0.63, up from $0.53, and 6.6% above consensus. Shares fell 12.3% to $23.02 after results. Analysts expect revenue flat and EPS around $2.24 to $2.26.
Over the past 7 days, alphai's AI scored 1 news story mentioning MD (Pediatrix Medical Group, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent MD coverage spans earnings, financial news and corporate actions.
Results show modest top-line growth from pricing and acquisitions, but volume declined and management flagged RCM collection tailwind dissipation in 2H 2026.
Q2 beat on Adjusted EPS and reaffirmed full-year EBITDA range, with revenue growth driven by acquisitions and same-unit reimbursement improvements.
Beat on revenue and EPS was outweighed by investor expectations, with the stock dropping sharply immediately after results.
Earnings preview centers on whether MD can sustain recent revenue/EPS beats and whether guidance and margins confirm the market’s low-volatility setup.
Near-term catalyst is fieldwork start and planned sampling, but the article provides no assay results or guidance.
alphai scores every news story that mentions MD with an AI model for sentiment and relevance, and aggregates insider trades from Pediatrix Medical Group, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Pediatrix Medical Group (MD) reported Q2 2026 revenue of $487.8 million, up 4% y/y, with adjusted EPS of $0.63 and adjusted EBITDA of $76.4 million. Net income was $39.8 million. Patient volume fell 2.1% y/y, while same-unit pricing rose 4%. CFO Rossi reaffirmed full-year 2026 adjusted EBITDA guidance of $280 million to $300 million.
6 min readPediatrix Medical Group, Inc. (MD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 md-ex99_1.htm EX-99.1 EX-99.1 FOR MORE INFORMATION: Kasandra H. Rossi Executive Vice President, Chief Financial Officer & Treasurer 954-692-7163 kasandra.rossi@pediatrix.com FOR IMMEDIATE RELEASE Pediatrix Medical Group Reports Second Quarter Results FORT LAUDERDALE, Fl
6 min readPediatrix Medical Group (NYSE:MD) reported Q2 CY2026 revenue of $487.8 million, up 4% year on year, beating market expectations by 2.1% (per the article). Non-GAAP adjusted EPS was $0.63, up from $0.53, and 6.6% above consensus. Shares fell 12.3% to $23.02 after results. Analysts expect revenue flat and EPS around $2.24 to $2.26.
4 min readPediatrix Medical Group (MD) is set to report Q2 earnings Tuesday before market open. The company previously reported $476.2M revenue, up 3.9% YoY, and beat EPS and slightly topped full-year EBITDA guidance. For Q2, analysts expect 1.9% revenue growth. The stock is down 3.2% over the past month; average price target is $24.50 vs $26.51.
3 min readMidland Exploration (TSX-V:MD) started a 2026 exploration program at its Lewis Gold Project in Québec under an option agreement with Barrick Mining (TSX:ABX). The plan covers 154 exclusive rights over about 86 km², including geological mapping and work at Red Giant and Golden Nest, with a second phase in September. Lewis is near the Nelligan deposit with 3.12Moz indicated and 5.16Moz inferred gold.
3 min readPediatrix Medical Group, Inc. (MD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0000893949 false 0000893949 2026-07-21 2026-07-21 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21,
2 min readPediatrix Medical Group, Inc. (MD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 md-ex99_1.htm EX-99.1 EX-99.1 FOR MORE INFORMATION: Kasandra H. Rossi Executive Vice President, Chief Financial Officer & Treasurer 954-692-7163 kasandra.rossi@pediatrix.com FOR IMMEDIATE RELEASE Pediatrix Medical Group Provides Second Quarter Update FORT LAUDERDALE, Fl
3 min readMidland Exploration Inc. (TSX-V: MD) said it has begun a 24-hole, 3,500 m drilling and prospecting campaign on its wholly owned Willbob gold project in the Labrador Trough, including the Kan sector. The company cited prior channel results such as 2.30 g/t Au over 8.95 m at Didgeridoo and said Canyon and Didgeridoo have not been drill-tested.
4 min readORDAN MARK S (Chief Executive Officer) sold (to issuer) 97,174 shares of Pediatrix Medical Group, Inc. (MD) on 2026-06-02.
3 min readPediatrix Medical Group (NYSE:MD) reported Q1 2026 results on May 5. Revenue rose to $476.2 million from $458.4 million a year earlier, beating the $465.7 million analyst estimate, according to the company. Adjusted EBITDA increased to $58.2 million from $49.2 million. Adjusted EPS was $0.44 vs. $0.33 a year ago, above the $0.38 estimate. The company expects full-year 2026 adjusted EBITDA of $280–$300 million.
5 min read
